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Abstract
Pregnancies complicated by gestational diabetes mellitus (GDM) are associated with increased risks of adverse maternal and fetal
outcomes. The risks of adverse pregnancy outcomes differ depending on the glucose values amongGDMpatients. For accurate and
effective prenatal counseling, it is necessary to understand the relationship between different maternal hyperglycemia values and the
severity of adverse outcomes. With this objective, this study reexamines the relationship between maternal hyperglycemia versus
maternal and perinatal outcomes in GDM patients. For this study, maternal hyperglycemia was diagnosed using the 2-step
diagnostic approach.
Medical records of 3434pregnantwomen,who received the 50-g glucose challenge test (GCT) betweenMarch 2001 andApril 2013,
were reviewed. As a result, 307 patients were diagnosed with GDM, and they were divided into 2 groups according to their fasting
glucose levels. A total of 171patients hadnormal fastingglucose level (<95mg/dL), and 136patients had abnormal fasting glucose level
(≥95mg/dL). The 50-g GCT results were subdivided by 20-unit increments (140–159, n=123; 160–179, n=84; 180–199, n=50; and
≥200, n=50), and the maternal and perinatal outcomes were compared against the normal 50-g GCT group (n=307).
Maternal fasting blood glucose (FBG) level showed clear association with adverse perinatal outcomes. The odds ratio (OR) of
macrosomia was 6.72 (95% CI: 2.59–17.49, P<0.001) between the 2 groups. The ORs of large for gestational age (LGA) and
neonatal hypoglycemia were 3.75 (95% CI: 1.97–7.12, P<0.001) and 1.65 (95% CI: 0.79–3.43, P=0.183), respectively. Also, the
results of the 50-g GCT for each category showed strong association with increased risks of adverse perinatal outcomes compared
to the normal 50-g GCT group. The OR of macrosomia (up to 20.31-fold), LGA (up to 6.15-fold), and neonatal hypoglycemia (up to
84.00-fold) increased with increasing 50-g GCT result.
Abbreviations: BMI = body mass index, FBG = fasting blood glucose, GCT = glucose challenge test, GDM = gestational
diabetes mellitus, LGA = large for gestational age, OGTT = oral glucose tolerance test.
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1. Introduction of 2% to 14% in all pregnant women.[1] GDM is associated withGestational diabetes mellitus (GDM) is deﬁned as glucose
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1maternal, fetal, and neonatal adverse outcomes such as cesarean
delivery, preeclampsia, shoulder dystocia, macrosomia, neonatal
hypoglycemia, and perinatal death. Although yet to be proven,
screening and treating GDM may contribute to prevent adverse
outcomes.[2]
The most commonly used screening and diagnostic methods
of GDM are ﬂawed because they give relatively poor negative
and positive predictive values. The 2-step diagnosis method, the
1-hour 50-g glucose challenge test (GCT), and the 3-hour 100-g
oral glucose tolerance test (OGTT) are currently used in the
United States, and the single-step 2-hour 75-g OGTT is used in
European countries.[3,4] In Korea, the 2-step diagnosis approach
has been used predominantly as in the United States, but several
hospitals have adopted new guidelines for the diagnosis of GDM.
It is also necessary to change the current counseling and
treatment approaches for GDM patients because perinatal
outcomes tend to differ according to glucose levels. Previous
studies have shown that rates of adverse outcomes increased with
increasing GCT subgroups.[5] Patients with 50-g GCTwithin 140
to 199mg/dL had 2.5-fold increasing risk of large for gestational
age (LGA) and 2.9-fold increasing risk of macrosomia. Langer
et al[6] demonstrated that every 10mg/dL increment in fasting
blood glucose (FBG) resulted in 15% increase in adverse
composite outcomes.
Figure 1. Distribution of the study population. OGTT=oral glucose tolerance test.
Cho et al. Medicine (2016) 95:36 MedicineThe purpose of this study is to evaluate the association between
perinatal outcomes and 50-g GCT values as well as FBG among
GDM women.2. Methods
A retrospective analysis of 3434 pregnant women who had 50-g
GCT was carried out between March 2001 and April 2013 at
Severance Hospital, Seoul, Korea. The approval was obtained
from the Institutional Review Board of Yonsei University Health
System. Informed consent was not required given the retrospec-
tive nature of the study.
Women with fetal anomalies, multiple gestations, overt
diabetes mellitus (DM), and hypertension were excluded from
the study. A total of 2631 pregnant women received the normal
50-g GCT and 803 received the100-g OGTT because their 50-g
GCT value was greater than 140mg/dL. As a result, 307 patients
were diagnosed with GDM (GDM group) and 496 showed false-
positive result (impaired glucose tolerance group).
A false-positive result was deﬁned as showing positive in the 1-
hour 50-g GCT but negative in the 3-hour 100-g OGTT. The
Carpenter and Coustan criteria were used to diagnose GDM.
GDM was deﬁned as showing 2 or more abnormal duration
(hours) of 100-g OGTT values: FBG of 95mg/dL or more; 180
mg/dL or more for 1-hour; 155mg/dL or more for 2-hours; and
140mg/dL or more for 3-hours. GDM patients were divided into
2 groups according to their FBG. A total of 171 patients had
normal FBG (<95mg/dL) and 136 patients had abnormal FBG
(≥95mg/dL) (Fig. 1). The 1-hour 50-g GCT result was also
divided into 20-unit increments, and these subgroups were used
to evaluate maternal and perinatal outcomes. A total of 307
pregnant women (the same number as GDM patients) were
randomly selected from the normal 1-hour 50-g GCT group (n=
2631) to be the control. The risks of adverse maternal and
perinatal outcomes for subgroups of the GDM group were then
analyzed and compared against the control group.
Maternal composite adverse outcomes included cesarean
delivery and preeclampsia, while fetal composite adverse
outcomes included LGA, APGAR score, intensive care unit
admission, neonatal hypoglycemia, and hyperbilirubinemia.2Preeclampsia was diagnosed according to the criteria of the
ACOG Practice Bulletin: new onset of blood pressure of 140/90
mmHg or more on 2 separate readings taken 6hours apart after
20 gestational weeks; and proteinuria of 300mg/24hours or
more. LGA was deﬁned as birth weight greater than the 90th
percentile compared with gestational age. Neonatal hypoglyce-
mia was deﬁned as blood glucose level of less than 40mg/dL, and
hyperbilirubinemia was deﬁned as bilirubin level of more than 5
mg/dL.
For statistical processing, the Chi-square test or Fisher exact
test was used for categorical variables and the 2-sample t test or
the Wilcoxon rank sum test was used for continuous variables.
Multiple logistic regression analysis was performed to estimate
the odds ratios (ORs) of adverse outcomes with adjustment for
confounders. Statistical analysis was performed using SAS
version 9.2 (SAS Institute, Inc., Cary, NC) and statistical
signiﬁcance was considered for P-values<0.05.3. Results
Based on the results of the 50-g GCT, the clinical characteristics
and perinatal outcomes of the impaired glucose tolerance (IGT)
group and the GDM group (Table 1) were compared. Signiﬁcant
differences were observed between the 2 groups in terms of their
maternal age, body mass index (BMI) before pregnancy and at
delivery, and family history of DM. For perinatal outcomes, the
GDM group showed higher incidence of cesarean delivery,
macrosomia, LGA, and neonatal hypoglycemia.
Among GDM patients, maternal characteristics and perinatal
outcomes are presented according to FBG (Table 2). Study
ﬁndings show statistical signiﬁcance in BMI before pregnancy
and at delivery, rate of cesarean section, prevalence of gestational
hypertension, gestational insulin therapy, and HbA1c at
diagnosis. Incidence of macrosomic newborn (3.5% for normal
glycemic vs 22.1% hyperglycemic group, P<0.001) and LGA
newborn (10.5% for normal glycemic vs 36.0% hyperglycemic
group, P<0.001) was higher in the fasting hyperglycemic group,
meeting the Carpenter and Coustan criteria. Moreover, the
prevalence of neonatal hypoglycemia was 9.4%, and 15.4%
in the normal glycemic and hyperglycemic groups, respectively
Table 1
Comparison of characteristics of IGT and GDM groups.
Variables IGT (n=496) GDM (n=307) P
Age, years 33.0±3.8 33.7±3.9 0.019
Primiparous 258 (52.0%) 151 (49.2%) 0.617
BMI before pregnancy, kg/m2 21.7±3.5 23.4±4.4 <0.001
Weight gain, kg 12.3±3.9 10.7±4.8 <0.001
BMI at delivery, kg/m2 26.5±3.7 27.5±4.5 0.001
Family history of DM, % 90 (18.2%) 86 (28.0%) 0.001
Gestational age at
delivery, weeks
39+0 (27+3–41+4) 38+2 (26+1–41+2) <0.001
Cesarean delivery, % 225 (45.4%) 181 (59.0%) <0.001
Gestational hypertension, % 17 (3.4%) 16 (5.2%) 0.216
Baby gender, male, % 258 (52.0%) 189 (61.6%) 0.008
Neonatal birth weight, g 3171±563 3209±684 0.409
Macrosomia, % 17 (3.4%) 36 (11.7%) <0.001
Large for gestational age, % 62 (12.5%) 67 (21.8%) 0.002
APGAR score at 1minute 7 (1–10) 7 (0–9) 0.005
APGAR score at 5minutes 8 (3–10) 8 (0–10) 0.230
NICU admission, % 98 (19.8%) 72 (23.5%) 0.213
Neonatal hypoglycemia, % 28 (5.7%) 37 (12.1%) 0.001
Neonatal hyperbilirubinemia, % 145 (29.2%) 90 (29.3%) 0.980




BMI=body mass index, DM=diabetes mellitus, GDM=gestational diabetes mellitus, IGT= impaired
glucose tolerance, NICU=neonatal intensive care unit.
Table 3
OR of perinatal outcomes for fasting glucose level ≥95mg/dL in
GDM group.
Outcomes OR 95% CI P
Macrosomia 6.72 2.59–17.49 <0.001
LGA 3.75 1.97–7.12 <0.001
Neonatal hypoglycemia 1.65 0.79–3.43 0.183
OR adjusted for age, parity, family history of DM, BMI at entry, and weight gain. CI= conﬁdence
interval, GDM=gestational diabetes mellitus, LGA= large for gestational age, OR= odds ratio.
Cho et al. Medicine (2016) 95:36 www.md-journal.com(P<0.001). To compare perinatal outcomes between the 2
groups, the odds ratio was calculated after controlling for
confounding factors (Table 3). Fasting hyperglycemia showed
strong association with adverse perinatal outcomes. The odds
ratio for perinatal outcomes was 6.72 (95% CI: 2.59–17.49, P<
0.001) with macrosomia, 3.75 (95% CI: 1.97–7.12, P<0.001)Table 2






BMI at prepregnancy, kg/m2 22.2±3.6
Weight gain, kg 10.8±4.0
BMI at delivery, kg/m2 26.5±3.7




Cesarean delivery, % 96 (56.1%)
Gestational hypertension, % 5 (2.9%)
Gestational insulin therapy, % 22 (12.9%)
HbA1c at diagnosis, % 5.7±0.4
Baby gender, male, % 103 (60.2%)
Neonatal birth weight, g 3063±617
Macrosomia, % 6 (3.5%)
Large for gestational age, % 18 (10.5 %)
APGAR score at 1 minute 7 (2–9)
APGAR score at 5 minutes 8 (3–10)
NICU admission, % 38 (22.2%)
Neonatal hypoglycemia, % 16 (9.4%)
Neonatal hyperbilirubinemia, % 52 (30.4%)
Glucose level after 50g
glucose challenge test, mg/dL
162.1±16.6
Fasting glucose level, mg/dL 82.1±7.1
BMI=body mass index, DM=diabetes mellitus, GDM=gestational diabetes mellitus, NICU=neonatal i
3with LGA, and 1.65 (95% CI: 0.79–3.43, P=0.183) with
neonatal hypoglycemia. The maternal and perinatal outcomes of
pregnant women with 50-g GCT result of over 140mg/dL were
further stratiﬁed into 20-unit increments (Table 4). The ﬁndings
showed signiﬁcant differences in BMI before pregnancy and at
delivery, incidence of gestational hypertension and gestational
insulin therapy, HbA1c at diagnosis of GDM,macrosomia, LGA,
and neonatal hypoglycemia. The 50-g GCT results were
categorized and the perinatal outcomes were compared with
50-g GCT normal group after adjusting for confounders
(Table 5). Increased 50-g GCT values in subgroups showed
relevance with higher risk of perinatal outcomes. The ORs of
macrosomia (up to 20.31-fold), LGA (up to 6.15-fold), and
neonatal hypoglycemia (up to 84.00-fold) were higher in
subgroups with higher 50-g GCT values. Among GDM patients,
the group with 50-g GCT level of 140 to 159mg/dL was found to
be associated with macrosomia (OR: 4.31, 95% CI: 1.42–13.13,
P=0.010) and neonatal hypoglycemia (OR: 17.27, 95% CI:
2.03–147.12, P=0.009) when compared against the normal
group. However, LGA (OR: 0.84, 95%CI: 0.40–1.73, P=0.628)
did not show statistical signiﬁcance. The subgroup in the 160 to



























Maternal and perinatal outcomes according to 50-g glucose challenge test in GDM patients.
Variables
50-g glucose challenge test, mg/dL
P140–159 (n=123) 160–179 (n=84) 180–199 (n=50) ≥200 (n=50)
Age years 33.7±4.1 33.3±3.6 33.5±3.7 34.2±3.9 0.622
Primiparous 72 (58.5%) 36 (42.9%) 22 (44.0%) 21 (42.0%) 0.040
BMI before pregnancy kg/m2 22.4±4.1 23.1±4.4 24.0±4.2 25.6±4.6 <0.001
Weight gain kg 12.9±4.1 13.0±4.0 13.1±4.1 12.8±4.2 0.859
BMI at delivery kg/m2 26.7±4.1 27.2±4.7 28.0±4.2 29.6±4.7 <0.001
Family history of DM % 30 (24.4%) 25 (29.8%) 18 (36.0%) 13 (26.0%) 0.455
Gestational age at delivery weeks 38+1 (29+0–41+1) 38+3 (27+1–41+1) 38+2 (26+1–41+1) 38+3 (33+1–41+2) 0.450
Cesarean delivery, % 69 (56.1%) 47 (56.0%) 34 (68.0%) 31 (62.0%) 0.455
Gestational hypertension, % 5 (4.1%) 4 (4.8%) 4 (8.0%) 3 (6.0%) 0.009
Gestational insulin therapy, % 24 (19.5%) 19 (22.6%) 14 (28.0%) 29 (58.0%) <0.001
HbA1c at diagnosis, % 5.6±0.4 5.8±0.5 5.9±0.6 6.6±0.9 <0.001
Baby gender, male, % 75 (61.0%) 49 (58.3%) 34 (68.0%) 31 (62.0%) 0.736
Neonatal birth weight, g 3024±655 3198±570 3307±819 3587±626 <0.001
Macrosomia, % 8 (6.5%) 8 (9.5%) 6 (12.0%) 14 (28.0%) <0.001
Large for gestational age, % 12 (9.8%) 15 (17.9%) 16 (32.0%) 24 (48.0%) <0.001
APGAR score at 1 minute 7 (2–9) 7 (0–9) 7 (4–8) 7 (2–9) 0.626
APGAR score at 5 minutes 8 (3–10) 8 (0–10) 8 (6–9) 8 (6–10) 0.783
NICU admission, % 33 (26.8%) 19 (22.6%) 12 (24.0%) 8 (16.0%) 0.499
Neonatal hypoglycemia, % 6 (4.9%) 12 (14.3%) 9 (18.0%) 10 (20.0%) 0.011
Neonatal hyperbilirubinemia, % 35 (28.5%) 29 (34.5%) 15 (30.0%) 11 (22.0%) 0.485
BMI=body mass index, DM=diabetes mellitus, GDM=gestational diabetes mellitus, NICU=neonatal intensive care unit.
Cho et al. Medicine (2016) 95:36 Medicine5.95, 95% CI: 1.92–18.49, P=0.002) and neonatal hypoglyce-
mia (OR: 53.72, 95% CI: 6.78–425.70, P<0.001). LGA (OR:
1.48, 95% CI: 0.73–3.03, P=0.279) showed the tendency to
increase but there was no statistical signiﬁcance. Also, the
subgroups in the 180 to 199mg/dL and the ≥200mg/dL ranges
showed a strong association with all adverse perinatal outcomes.
Therefore, risks of adverse perinatal outcomes increased as the
values of 50-g GCT results increased.
4. Discussion
This study investigated the maternal and perinatal outcomes
according to FBG and 50-g GCT values in GDM pregnantTable 5
ORof perinatal outcomes according to 50-g glucose challenge test
values in GDM patients.
Outcomes OR 95% CI P
Macrosomia
<140 (mg/dL) (n=307) 1.00
140–159 (n=123) 4.31 1.42–13.13 0.010
160–179 (n=84) 5.95 1.92–18.49 0.002
180–199 (n=50) 7.38 2.15–25.31 0.002
≥200 (n=50) 20.31 6.62–62.31 <0.001
LGA
<140 1.00
140–159 0.84 0.40–1.73 0.628
160–179 1.48 0.73–3.03 0.279
180–199 3.24 1.50–7.00 0.003
≥200 6.15 2.89–13.10 <0.001
Neonatal hypoglycemia
<140 1.00
140–159 17.27 2.03–147.12 0.009
160–179 53.72 6.78–425.70 <0.001
180–199 73.53 8.86–609.98 <0.001
≥200 84.00 10.03–703.27 <0.001
OR adjusted for age, parity, family history of DM, BMI at entry, and weight gain. BMI=body mass
index, CI= conﬁdence interval, GDM=gestational diabetes mellitus, LGA= large for gestational age,
OR= odds ratio.
4women. The risks of macrosomia, LGA, and neonatal hypogly-
cemia increased with fasting hyperglycemia and higher 50-g GCT
values. Study ﬁndings also showed that the association between
fasting hyperglycemia and adverse perinatal outcomes remain to
be signiﬁcant after adjustment for potential confounders.
Previous studies have found that postprandial hyperglycemia
was associated with excessive fetal growth in GDM patients
requiring insulin therapy or pregestational diabetes patients.[7,8]
Other studies have indicated that meal-related glucose threshold
measurement did not increase the risk of adverse fetal out-
comes.[9] Recently, other researches have demonstrated signiﬁ-
cant association between fasting and 1-hour 75-g OGTT glucose
values with LGA newborns among GDM women. It has been
reported that strict glucose control in this risk group may be
necessary in order to avoid LGA newborns.[10]
It has been emphasized in many studies that FBG is an
important factor in GDM screening as well as in predicting
neonatal adverse outcomes. Herrera et al[11] investigated the
importance of FBG in screening for GDM. GDMwomen with an
isolated abnormal FBG were more likely to need hypoglycemic
agents to obtain good glycemic control. The signiﬁcance and
magnitude of this association was consistent with the results of
this study. In the abnormal FBG group, 47.1% (64/136) of GDM
patients needed gestational insulin therapy to control the blood
glucose but in the normal FBG group (P<0.001), only 12.9%
(22/171) of pregnant women who were diagnosed with GDM
required insulin treatment.
The HAPO studies[12,13] have demonstrated the continuously
increasing relationship between maternal blood glucose levels
and adverse perinatal outcomes such as frequency of LGA,
neonatal hypoglycemia, cord blood serum C-peptide level above
the 90th percentile, and primary cesarean section delivery.
However, these studies are based on the single step 75-g OGTT,
and GDM was diagnosed using the International Association of
Diabetes and Pregnancy Study Groups (IADPSG) criteria. In the
HAPO studies, the outcomes were compared after categorizing
fasting, 1-hour, and 2-hour glucose values. In contrast, this study
Cho et al. Medicine (2016) 95:36 www.md-journal.comis based on the 2-step diagnosis of GDM, and the outcomes of the
50-g GCT values and the FBG of 100-g OGTT were compared
against each other. The outcomes found in this study give a more
accurate picture of the situation in Korea, where the 2-step
diagnosis is predominantly used. In addition, without adjusting
for confounding factors, such as prepregnancy BMI and
gestational weight gain, adverse outcome risks may have been
overestimated in other earlier studies. However, in this study, the
relation between maternal hyperglycemia and adverse perinatal
outcomes were analyzed after adjusting for BMI before
pregnancy and gestational weight gain, because BMI is also
related to maternal and perinatal outcomes in GDM patients.
FBG has been used as the most important indicator for the
diagnosis of DM in nonpregnant adults because it reﬂects
impaired insulin secretion and resistance.[14,15] FBG values tend
to stay constant throughout the entire period of pregnancy and
this is also true for nonpregnant patients. FBG values have less
individual variation compared to other glucose values; therefore,
abnormal FBG level is a signiﬁcant indicator in diagnosing GDM.
At present, FBG is a good screening test for GDM with
advantages such as simple procedure, reasonable cost, reproduc-
ibility, easy access, and wide acceptance.[15] Recently, other
studies have reported that abnormal FBG alone is capable of
detecting 50% of pregnant women with GDM from a pool of
women who had already been diagnosed with GDM with
another screening method. If combined with the 2-hour plasma
glucose level, another 25%of pregnant womenwithGDMcan be
detected.[16] In 2016, Park et al[17] developed a more practical
and efﬁcient screening tool using FBG and prepregnancy BMI for
predicting adverse outcomes of GDM. This new screening tool
focused on predicting the maternal and perinatal adverse
outcomes of GDM patients.
The ﬁndings of this study show that BMI before pregnancy,
BMI at delivery, HbA1c value at diagnosis, and the application of
gestational insulin therapy were much higher in the abnormal
FBG group. Several studies have indicated that maternal
prepregnancy BMI was associated with the risk of GDM. Sacks
et al[18] conﬁrmed that maternal BMI had a powerful impact
upon fetal birth weight. Therefore, GDM patients with both
higher BMI and abnormal FBG values can have potentially worse
perinatal outcomes. This study also showed that abnormal FBG
values according to the Carpenter and Coustan criteria had
signiﬁcance association with higher incidence of LGA, macro-
somia, and neonatal hypoglycemia.
In addition, adverse perinatal outcomes according to different
50-g GCT values among GDM patients were evaluated in this
study. The risks of macrosomia, LGA, and neonatal hypoglyce-
mia increased with increasing 50-g GCT values. Several studies
have examined the relationship of 50-g GCT and perinatal
outcomes. In 1987, Leikin et al[19] reported that the false-positive
GCT group (GCT values of 135mg/dL or more but normal
OGTT values) had higher incidence of macrosomia compared
with the normal GCT group (11.9% vs 6.4%, P=0.009).
Recently, other retrospective cohort studies also showed that
false-positive GCT is an independent risk factor for adverse
perinatal outcomes (OR: 5.96, 95% CI: 1.3–10.3).[20] The
ﬁndings of this study suggest that the risks of the macrosomia (up
to 20.31-fold), LGA (up to 6.15-fold), and neonatal hypoglyce-
mia (up to 84.00-fold) increased with higher 50-g GCT values.
More importantly, 50-g GCT values in the range of 140 to 159
mg/dLwere not associatedwith LGA compared to the normal 50-
g GCT group. The OR for neonatal hypoglycemia was
exceptionally high. These results should be interpreted with5caution since conﬁdence intervals were very wide due to a limited
number of cases in the 50-g GCT normal group.
In 2013, Figueroa et al[5] evaluated the relationship between
50-g GCT values and perinatal outcomes in mild GDM patients,
and showed that GCT values of 140mg/dL or more were
associated with an increase of composite perinatal outcomes,
LGA, andmacrosomia. However, there was no evaluation for the
group with GCT value of 200mg/dL or more. They only included
mild GDM group with fasting glucose value less than 95mg/dL.
The strength of this study is that a full spectrum of GDM patients
were examined using the Carpenter and Coustan criteria,
including the group with 50-g GCT higher than 200mg/dL.
Therefore, it was possible to evaluate the continuous 50-g GCT
values in the lower or upper ranges. This study also included
normal and abnormal fasting glucose groups and the abnormal
FBG group tended to have a greater risk for adverse perinatal
outcomes.
The limitation of this study is that it is a retrospective study. A
randomized clinical trial of a larger scale, using prospectively
collected data from a well-characterized trial cohort, is ideal and
necessary to validate the ﬁndings of this study. The inﬂuence of
GDM management on perinatal outcomes was not considered
in this study. All GDM women were treated to achieve
the recommended value of their glycemic proﬁles and 28.0%
(86/307) of the pregnant women with GDM needed insulin
therapy. Even without the inﬂuence of GDM management,
maternal hyperglycemia was still associated with adverse
perinatal outcomes. In addition, long-term health complications
such as childhood obesity, impaired insulin sensitivity, or type 2
diabetes mellitus were not considered for in this study.[21]
In conclusion, fasting hyperglycemia is a strong predictor for
poor perinatal outcomes in GDM patients. Also, composite
perinatal outcomes such as macrosomia, LGA, and neonatal
hypoglycemia are more frequent with increasing 50-g GCT
values. Therefore, more attention and care should be given during
prenatal counseling, as well as more active therapeutic interven-
tion taken when necessary with closer fetal monitoring, with the
objective to reduce adverse perinatal outcomes in GDM patients
with abnormal FBG or high 50-g GCT values.
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